Cargando…

Methylprednisolone pulse therapy: An alternative management of severe COVID-19

We present two cases of severe COVID-19 that were rejected by medical institutions. The management of the disease was done at home with methylprednisolone (MP) pulse therapy for three days. This resulted in a favorable evolution and resolution of most symptoms. COVID-19 infection presents as asympto...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauñe, Patricia Merab, Bryce-Alberti, Mayte, Portmann-Baracco, Arianna Sibila, Accinelli, Roberto Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502379/
https://www.ncbi.nlm.nih.gov/pubmed/32995261
http://dx.doi.org/10.1016/j.rmcr.2020.101221
_version_ 1783584213388230656
author Sauñe, Patricia Merab
Bryce-Alberti, Mayte
Portmann-Baracco, Arianna Sibila
Accinelli, Roberto Alfonso
author_facet Sauñe, Patricia Merab
Bryce-Alberti, Mayte
Portmann-Baracco, Arianna Sibila
Accinelli, Roberto Alfonso
author_sort Sauñe, Patricia Merab
collection PubMed
description We present two cases of severe COVID-19 that were rejected by medical institutions. The management of the disease was done at home with methylprednisolone (MP) pulse therapy for three days. This resulted in a favorable evolution and resolution of most symptoms. COVID-19 infection presents as asymptomatic disease, non-severe symptomatic disease, and severe respiratory inflammatory disease. The first two forms are dependent on viral response and a “cytokine storm” is responsible for the progression into severe disease. Glucocorticoids (GC) reduce inflammation by different mechanism depending of their concentration. Pulses lead to overall apoptosis of immune cells. Studies using pulse MP as treatment for SARS-CoV-1 showed clinical improvement and decreased incidence of ARDS compared with patients who received low dose steroid treatment. Inhibition of excessive inflammation through timely administration of GC in the early stage of inflammatory cytokine storm effectively prevents the occurrence of ARDS.
format Online
Article
Text
id pubmed-7502379
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75023792020-09-28 Methylprednisolone pulse therapy: An alternative management of severe COVID-19 Sauñe, Patricia Merab Bryce-Alberti, Mayte Portmann-Baracco, Arianna Sibila Accinelli, Roberto Alfonso Respir Med Case Rep Case Report We present two cases of severe COVID-19 that were rejected by medical institutions. The management of the disease was done at home with methylprednisolone (MP) pulse therapy for three days. This resulted in a favorable evolution and resolution of most symptoms. COVID-19 infection presents as asymptomatic disease, non-severe symptomatic disease, and severe respiratory inflammatory disease. The first two forms are dependent on viral response and a “cytokine storm” is responsible for the progression into severe disease. Glucocorticoids (GC) reduce inflammation by different mechanism depending of their concentration. Pulses lead to overall apoptosis of immune cells. Studies using pulse MP as treatment for SARS-CoV-1 showed clinical improvement and decreased incidence of ARDS compared with patients who received low dose steroid treatment. Inhibition of excessive inflammation through timely administration of GC in the early stage of inflammatory cytokine storm effectively prevents the occurrence of ARDS. Elsevier 2020-09-12 /pmc/articles/PMC7502379/ /pubmed/32995261 http://dx.doi.org/10.1016/j.rmcr.2020.101221 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sauñe, Patricia Merab
Bryce-Alberti, Mayte
Portmann-Baracco, Arianna Sibila
Accinelli, Roberto Alfonso
Methylprednisolone pulse therapy: An alternative management of severe COVID-19
title Methylprednisolone pulse therapy: An alternative management of severe COVID-19
title_full Methylprednisolone pulse therapy: An alternative management of severe COVID-19
title_fullStr Methylprednisolone pulse therapy: An alternative management of severe COVID-19
title_full_unstemmed Methylprednisolone pulse therapy: An alternative management of severe COVID-19
title_short Methylprednisolone pulse therapy: An alternative management of severe COVID-19
title_sort methylprednisolone pulse therapy: an alternative management of severe covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502379/
https://www.ncbi.nlm.nih.gov/pubmed/32995261
http://dx.doi.org/10.1016/j.rmcr.2020.101221
work_keys_str_mv AT saunepatriciamerab methylprednisolonepulsetherapyanalternativemanagementofseverecovid19
AT brycealbertimayte methylprednisolonepulsetherapyanalternativemanagementofseverecovid19
AT portmannbaraccoariannasibila methylprednisolonepulsetherapyanalternativemanagementofseverecovid19
AT accinellirobertoalfonso methylprednisolonepulsetherapyanalternativemanagementofseverecovid19